 |
CuraGen Reports First Quarter 2008 Financial Results
Apr 22, 2008 |
16.1 KB
|
| |
BRANFORD, Conn., April 22, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- CuraGen Corporation (Nasdaq: CRGN) today reported its financial results for the first quarter of 2008. For the quarter ended March 31, 2008, CuraGen reported a net loss of $6.8 million, or $0.12 per share, compared to a net loss of $17.0 million, or $0.31 per share, f...
|
|
|
CuraGen Sells Ownership of Belinostat to TopoTarget A/S
Apr 22, 2008 |
13.7 KB
|
| |
BRANFORD, Conn., April 22, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company, announced today that it has sold its ownership in belinostat, a Phase I/II histone deacetylase inhibitor, to TopoTarget A/S (Copenhagen Stock Exchange: TOPO) for approximately $39 million ...
|
|
|
CuraGen Advances CR011-vcMMAE into Phase II
Apr 9, 2008 |
12.8 KB
|
| |
BRANFORD, Conn., April 9, 2008, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced today that it has advanced CR011-vcMMAE, an antibody-drug conjugate (ADC), into Phase II for the treatment of patients with unresectable Stage III and St...
|
|
|
CuraGen to Present at the BIO CEO & Investor Conference
Feb 12, 2008 |
8.8 KB
|
| |
BRANFORD, Conn., Feb 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- CuraGen Corporation (Nasdaq: CRGN) announced today that Timothy M. Shannon, M.D., President and Chief Executive Officer, will present at the BIO CEO & Investor Conference on Wednesday, February 13, 2008, at 3:30 p.m. Eastern Standard Time.
Access to a live webcast o...
|
|
|
CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
Jan 31, 2008 |
16.5 KB
|
| |
BRANFORD, Conn., Jan 31, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- CuraGen Corporation (Nasdaq: CRGN) today reported its consolidated financial results for the fourth quarter and fiscal year ended December 31, 2007.
CuraGen reported a loss from operations for the fourth quarter of 2007 of $11.0 million, or $0.20 per share, which in...
|
|
|
CuraGen Corporation Receives Notification from NASDAQ
Jan 29, 2008 |
11.3 KB
|
| |
BRANFORD, Conn., Jan 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, today announced that it received a letter, dated January 28, 2008, from The NASDAQ Stock Market, notifying CuraGen that during the preceding 30 consecutive trading days, ...
|
|
|
CuraGen to Discuss Fourth Quarter and Year End 2007 Financial Results Via Conference Call on January 31, 2008
Jan 24, 2008 |
9.6 KB
|
| |
BRANFORD, Conn., Jan 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced today that Company executives will be holding a conference call to discuss CuraGen's fourth quarter and year end 2007 financial results at 11:00 a.m. Eastern St...
|
|
|
CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
Dec 20, 2007 |
11.9 KB
|
| |
BRANFORD, Conn., Dec 20, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, today announced the appointment of Sean Cassidy, as Vice President and Chief Financial Officer effective January 1, 2008. CuraGen also announced today that David M. Wurze...
|
|
|
CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
Dec 19, 2007 |
14.5 KB
|
| |
BRANFORD, Conn., Dec 19, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase II open-label, multi-center clinical trial evaluating the...
|
|
|
CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA
Dec 10, 2007 |
18.6 KB
|
| |
BRANFORD, Conn., Dec 10, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today that updated clinical trial results on intravenous belinostat for the treatment of T-cell lymphomas w...
|
|
|
